Qritive, a leading provider of AI solutions for pathology labs worldwide, has secured multi-year contracts with renowned diagnostic centers and hospitals in India, including Metropolis Healthcare, Rajiv Gandhi Cancer Institute, and CÃ…ÂŒRE Diagnostics. Through these collaborations, Qritive aims to drive the adoption of artificial intelligence (AI) in pathology workflows, revolutionizing diagnostic practices and enhancing patient care.
The partnership between Qritive and these esteemed healthcare institutions signifies a significant advancement in modernizing pathology practices through the integration of AI technology. By leveraging Qritive’s Pantheon image management system (IMS) and AI products, these centers and hospitals are taking a pioneering step in adopting AI to improve diagnostic precision, streamline operational efficiency, and ultimately elevate patient care.
Metropolis Healthcare CEO, Mr. Surendran Chemmenkottil, expressed his enthusiasm for the transformative journey with Qritive, highlighting the immense potential it holds for advancing pathology capabilities. He emphasized that the integration of Qritive’s AI-powered platform into their workflows will revolutionize precision, timeliness, and personalized diagnosis. Furthermore, this collaboration reinforces Metropolis Healthcare’s commitment to setting new standards in cancer care, particularly in supporting clinicians in making effective treatment decisions for prostate cancer detection.
Bruno Occhipinti, CEO of Qritive, expressed pride in working alongside forward-looking healthcare institutions and the opportunity to leverage AI to improve patient outcomes and support pathologists. Occhipinti added that Qritive’s deep tech solutions will contribute to closing the gap in cancer care, aligning with the aspirations of World Cancer Day celebrated on February 4th.
The partnership with Qritive is equally exciting for CÃ…ÂŒRE Diagnostics, as stated by CEO Mr. Dinesh Chauhan. The collaboration will strengthen diagnostic precision, leading to improved patient outcomes and reinforcing CÃ…ÂŒRE Diagnostics’ commitment to delivering excellence in clinical care. Chauhan also highlighted the potential for the development of new AI services for the diagnosis of rare diseases resulting from this collaboration.
Qritive’s AI platform has already revolutionized pathology workflows, with clinical studies demonstrating up to 90% faster diagnoses and 80% less discordance. These improvements in diagnosis accuracy significantly benefit cancer patient care.
Overall, Qritive’s partnership with Metropolis Healthcare, Rajiv Gandhi Cancer Institute, and CÃ…ÂŒRE Diagnostics marks a monumental step in the adoption of AI in pathology workflows in India. This collaboration harnesses the power of AI technology to enhance diagnostic precision, streamline processes, and ultimately improve patient outcomes, highlighting the dedication of these institutions to advancing healthcare practices.
